Abstract
An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB1, CB2) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB2 activation. Development of CB2 agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB2 activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.
| Original language | English |
|---|---|
| Pages (from-to) | 608-620 |
| Number of pages | 13 |
| Journal | Journal of Neuroimmune Pharmacology |
| Volume | 8 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 Jun 2013 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cannabinoid receptor
- Endocannabinoids
- Endothelial cells
- HIV-1
- Medical marijuana
- Monocyte/macrophage
ASJC Scopus subject areas
- Neuroscience (miscellaneous)
- Immunology and Allergy
- Immunology
- Pharmacology
Fingerprint
Dive into the research topics of 'Cannabinoid receptor 2: Potential role in immunomodulation and neuroinflammation'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver